Journal article
UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
Abstract
Abstract
Glioblastoma (GBM) is the common malignant brain tumor in adults, accounting for approximately 15% of all CNS tumors, and 48.6% of malignant brain tumors, with a median survival of approximately 15 months, and minimal clinical progress having been made in the past two decades. GBM is characterized by extensive inter- and intra-tumoral heterogeneity as well as an extremely immunosuppressive tumor microenvironment. Following …
Authors
Maich W; Shaikh V; Puri A; Anand A; Rosotti M; Savage N; Chokshi C; Suk Y; Savage N; Gwynne W
Journal
Neuro-Oncology Advances, Vol. 5, No. Suppl 2, pp. i10–i10
Publisher
Oxford University Press (OUP)
Publication Date
July 12, 2023
DOI
10.1093/noajnl/vdad071.041
ISSN
0801-3284